Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 39Melanoma 34Gliosarcoma 34Brain Neoplasms 33Breast Neoplasms 31Lymphoma 24Neoplasm Metastasis 23Astrocytoma 23Colonic Neoplasms 20Multiple Myeloma 19Leukemia, Myeloid, Acute 19Leukemia 19Carcinoma, Non-Small-Cell Lung 19Prostatic Neoplasms 18Lymphoma, Non-Hodgkin 18Colorectal Neoplasms 18Central Nervous System Neoplasms 18Carcinoma, Renal Cell 18Rectal Neoplasms 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Neoplasms 17Lymphoma, Large B-Cell, Diffuse 17Leukemia, Lymphocytic, Chronic, B-Cell 16Hodgkin Disease 16Squamous Cell Carcinoma of Head and Neck 15Oligodendroglioma 15Pancreatic Neoplasms 14Myelodysplastic Syndromes 14Lung Neoplasms 14Sarcoma 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × NIH × Lymphangioleiomyomatosis × Clear all
NCT01799538 2026-05-01

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
100 enrolled

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡